The European healthcare technology sector has entered a protracted period of structural realignment, precipitated by the breakdown of the historical venture capital funding escalator. Between 2020 and 2021, zero-interest-rate monetary policies and temporary pandemic tailwinds channeled speculative capital into early-stage digital health platforms, creating inflated entry valuations and subsidising unsustainable operational burn rates.

Lanas has entered into a definitive agreement to acquire the primary care software platform indici, committing NZ$150 million over a two year deployment schedule to accelerate its digital health footprint across New Zealand. This capital injection forms part of a multi year expansion program that lifts the group's aggregate enterprise investment in the domestic market toward NZ$200 Million. Formed in late 2025 following the acquisition of Clanwilliam Group by founder and Chie

The convergence of biopharmaceuticals and consumer health technology reached an institutional milestone with Eli Lilly and Company’s disclosed interest in purchasing up to $100 million in common stock during the initial public offering of Oura Inc.. Lined up alongside an indicated cornerstone commitment of up to $300 million from Dragoneer Investment Group, the joint commitments represent approximately $400 million, or nearly 19% of the wearable maker’s public offering.

The trajectory of artificial intelligence (AI) in healthcare reflects a transformation from rigid, symbolic logic systems to statistical deep learning architectures, culminating in self-reasoning, multimodal foundation models. This technological maturation has not occurred in isolation; rather, it has been driven by the co-evolution of algorithmic breakthroughs, hardware acceleration, regulatory frameworks, and clinical reimbursement structures.

The primary client profile for Nelson Advisors comprises clinically originated or founder-led enterprises generating annual revenues between €5 Million and €50 Million, operating EBITDA from €1 Million to €10 Million, and maintaining head counts of 20 to 250 personnel. These organisations typically possess established, scalable technologies but lack in-house corporate development infrastructure to navigate institutional M&A processes, cross-border regulatory hurdles, and comp